{
    "pmcid": "11745544",
    "qa_pairs": {
        "How do protein language models (PLMs) like ESM improve predictive performance in nucleic acid-binding residue prediction?": [
            "By capturing functional motifs and domains as 'words' in a sequence.",
            "By directly sequencing nucleic acids to identify binding residues.",
            "By using chemical properties of amino acids to predict binding sites.",
            "By simulating protein folding to determine binding residues."
        ],
        "What advantage does ESM provide in the design of nanobodies for SARS-CoV-2?": [
            "High throughput and precision in analyzing protein sequences.",
            "Ability to synthesize nanobodies in vitro.",
            "Capability to directly neutralize viral particles.",
            "Enhanced visualization of protein structures."
        ],
        "What challenge related to ESM is highlighted in the context of nanobody design?": [
            "Cross-predictions where residues might be misclassified between different types of nucleic acids.",
            "Inability to process large protein sequences efficiently.",
            "Lack of accuracy in predicting protein tertiary structures.",
            "Difficulty in distinguishing between similar viral proteins."
        ],
        "What future research direction is suggested for improving PLMs like ESM in the context of viral proteins?": [
            "Developing PLMs specifically tailored for viral proteins and their interactions with antibodies.",
            "Increasing the computational speed of existing PLMs.",
            "Integrating PLMs with traditional laboratory techniques.",
            "Focusing on the development of PLMs for bacterial proteins."
        ],
        "What is one of the key applications of Evolutionary Scale Modeling (ESM) mentioned in the context of SARS-CoV-2 nanobody design?": [
            "Predicting and optimizing binding sites on viral proteins like the spike protein.",
            "Developing vaccines for SARS-CoV-2 variants.",
            "Creating antiviral drugs targeting SARS-CoV-2 replication.",
            "Designing diagnostic tests for SARS-CoV-2 infection."
        ]
    }
}